Pfizer (PFE) and partner BioNTech (BNTX) announced that a phase III study evaluating an mRNA-based combination vaccine candidate against influenza and COVID-19 missed one of its two primary immunogenicity objectives. The vaccine combines Pfizer’s investigational mRNA-based influenza vaccine candidate with it and BioNTech’s popular marketed COVID-19 vaccine called Comirnaty. The study was conducted in more than 8000 healthy individuals aged 18-64.The study’s two primary immunogenicity objectives were to demo ...